Clinical Trials

August 31st, 2017

At most points in the treatment process, you can talk to your doctor about participating in a clinical trial. Some treatments will make you ineligible for some clinical trials later on, so it's a good idea to find out your clinical trial options early in your treatment process.

Inflammatory Breast Cancer

August 29th, 2017

Inflammatory breast cancer is a type of breast cancer in which cancer cells block lymph vessels in the skin of the breast, causing it to become red and swollen.
How is inflammatory breast cancer diagnosed?
Inflammatory breast cancer progresses very quickly, and at diagnosis, is considered either stage III or IV. Because there is often no lump present in the breast, this type of cancer can be difficult to diagnose through a physical examination or mammogram.


August 29th, 2017

If breast cancer cells test negative for estrogen receptors, progesterone receptors, and the HER2 protein, the cancer is called triple-negative. Triple negative breast cancer tends to be more aggressive with a higher chance of systemic recurrence.
How is triple-negative breast cancer diagnosed?
Triple-negative breast cancer is diagnosed after lab tests measuring the presence of hormone receptors (estrogen and progesterone) and HER2 genes and proteins.

HER2 Positive (human epidermal growth factor receptor 2 positive)

August 29th, 2017

HER2-positive breast cancer cells have a high amount of human epidermal growth factor receptor 2 genes and HER2 proteins on cancer cells.
How is HER2-positive breast cancer diagnosed?
A lab test will measure the presence of HER2 receptor proteins on the cancer cells and how much HER2 protein is being made in a tissue sample.

Hormone Receptor Positive (ER+, PR+, or both)

August 29th, 2017

Hormone receptors are proteins on the surface of all cells, including normal breast cells and some breast cancer cells, that help to mediate how hormones such as estrogen interact with cells; they may also stimulate cell growth.

Breast cancer cells can overexpress (be positive for) either estrogen receptors (ER+), progesterone receptors (PR+), or both.

LCIS (Lobular Carcinoma in Situ)

August 29th, 2017

LCIS is a condition in which abnormal but noncancerous cells are found in the breast lobules, which are not cancer cells. LCIS can be considered Stage 0 since it is noninvasive and has not spread outside the breast lobules.

LCIS cells seem not to directly develop into invasive cancer.

DCIS (Ductal Carcinoma in Situ)

August 29th, 2017

DCIS is a noninvasive condition referring to abnormal cells in the lining of the breast duct that have not spread to other tissues. It is possible for DCIS to become invasive cancer and spread to other parts of the body, so treatment can reduce the likelihood of recurrence.

Treatment for Triple Negative Breast Cancer

August 29th, 2017

Triple negative breast cancer is hormone receptor negative (ER- and PR-) and HER2 negative, which disqualifies it from being treated with most targeted therapies and hormone therapies. This kind of cancer is usually treated with chemotherapy, sometimes in the neoadjuvant (pre-surgery) setting, although more research is needed to determine if neoadjuvant chemo actually improves response.

Targeted Therapy (for HER2+ breast cancer)

August 29th, 2017

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer. Targeted therapies select specific cells to attack, leaving healthy cells alone. They are often used with other types of therapy suited to specific types of breast cancer.

Hormonal Therapy (for hormone receptor positive breast cancer)

August 29th, 2017

Hormone (endocrine) therapy is a systemic, targeted treatment available for certain women who have estrogen positive (ER+ (ER positive, estrogen receptor positive) or PR+ (PR positive, progesterone receptor positive)) tumors. It can be given along with chemotherapy, or in place of it.